What are the indications for Ripotinib?

Repotrectinib (Repotrectinib) is a new oral third-generation tyrosine kinase inhibitor developed to target ROS1 and NTRK fusion mutations. It has a highly selective small molecule structure. Its mechanism of action is to inhibit tumor growth and metastasis by inhibiting the ROS1 and NTRK fusion protein signaling pathways and blocking the proliferation signal transduction of abnormal cells. Ripotinib has currently received accelerated approval from the US FDA for the treatment of patients with specific types of solid tumors, especially showing great promise in the field of ROS1-positive non-small cell lung cancer (NSCLC).

In terms of specific indications, Ripotinib is used to treat adult patients with locally advanced or metastatic NSCLCROS1-positive NSCLC. Such patients are often resistant to first-generation ROS1 inhibitors or have genetic mutations that lead to poor efficacy. Compared with previous treatment options, such as crizotinib, reprotinib has stronger activity against drug-resistant mutation sites such as G2032R, thus providing a new treatment option for patients with relapse or treatment failure.

In addition to lung cancer, Ripotinib is also suitable for patients with solid tumors with NTRK gene fusion, including adults and children aged 12 years and above. Although this type of fusion gene is rare, it can be found in a variety of tumor types, such as thyroid cancer, salivary gland cancer, soft tissue sarcoma, etc. For patients with this type of NTRK fusion-positive solid tumors, repotinib, as a tissue-independent targeted therapy drug, represents a major progress in the direction of precision treatment.

Compared with traditional chemotherapy, Ripotinib treatment has the advantages of more controllable side effects, clearer targets, and faster clinical response. It especially shows excellent penetration and target affinity in patients with brain metastases or drug-resistant mutations, making it an important treatment option for patients with ROS1 and NTRK mutations. In the future, as more clinical research data accumulates, its scope of indications may be further expanded to include other kinase fusion-related refractory solid tumors.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html